Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00414609 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Aliskiren in Post Myocardial Infarction Patients (ASPIRE)
A Phase 3 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 820
- Enrollment target
NCT00414609 is a Phase 3 study that has completed, run by Novartis. The registered enrollment target is 820 participants.
The verdict
NCT00414609, a Phase 3 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 820 participants
- Enrollment target
Study Summary
The core and extension studies assessed the safety and efficacy of aliskiren when added to optimized standard therapy in patients that have had a high risk acute myocardial infarction (heart attack).
Interventions
- DRUG placebo
- DRUG Aliskiren
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 820 participants |
| Start Date | 2006-12 |
| Est. Completion | 2011-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00414609
The ClinicalTrials.gov registry entry for NCT00414609 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 820 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00414609 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00414609 about?
NCT00414609 is a clinical study titled "Safety and Efficacy of Aliskiren in Post Myocardial Infarction Patients (ASPIRE)". The core and extension studies assessed the safety and efficacy of aliskiren when added to optimized standard therapy in patients that have had a high risk acute myocardial infarction (heart attack).
What is the current status of trial NCT00414609?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 820 participants. The study started on 2006-12. Estimated completion is 2011-07.
What interventions are being tested in trial NCT00414609?
The interventions under investigation include: placebo (DRUG), Aliskiren (DRUG).
Who is sponsoring clinical trial NCT00414609?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.